Antimalarial Activity of Orally Administered Curcumin Incorporated in Eudragit((R))-Containing Liposomes

dc.contributor.authorMartí Coma-Cros, Elisabet
dc.contributor.authorBiosca, Arnau
dc.contributor.authorLantero, Elena
dc.contributor.authorManca, Maria Letizia
dc.contributor.authorCaddeo, Carla
dc.contributor.authorGutiérrez, Lucía
dc.contributor.authorRamírez, Miriam
dc.contributor.authorBorgheti Cardoso, Livia Neves
dc.contributor.authorManconi, Maria
dc.contributor.authorFernàndez Busquets, Xavier
dc.date.accessioned2018-06-05T07:19:16Z
dc.date.available2018-06-05T07:19:16Z
dc.date.issued2018-05-04
dc.date.updated2018-05-23T17:59:35Z
dc.description.abstractCurcumin is an antimalarial compound easy to obtain and inexpensive, having shown little toxicity across a diverse population. However, the clinical use of this interesting polyphenol has been hampered by its poor oral absorption, extremely low aqueous solubility and rapid metabolism. In this study, we have used the anionic copolymer Eudragit(®) S100 to assemble liposomes incorporating curcumin and containing either hyaluronan (Eudragit-hyaluronan liposomes) or the water-soluble dextrin Nutriose(®) FM06 (Eudragit-nutriosomes). Upon oral administration of the rehydrated freeze-dried nanosystems administered at 25/75 mg curcumin·kg(−1)·day(−1), only Eudragit-nutriosomes improved the in vivo antimalarial activity of curcumin in a dose-dependent manner, by enhancing the survival of all Plasmodium yoelii-infected mice up to 11/11 days, as compared to 6/7 days upon administration of an equal dose of the free compound. On the other hand, animals treated with curcumin incorporated in Eudragit-hyaluronan liposomes did not live longer than the controls, a result consistent with the lower stability of this formulation after reconstitution. Polymer-lipid nanovesicles hold promise for their development into systems for the oral delivery of curcumin-based antimalarial therapies.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1422-0067
dc.identifier.pmid29734652
dc.identifier.urihttps://hdl.handle.net/2445/122777
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.3390/ijms19051361
dc.relation.ispartofInternational Journal of Molecular Sciences, 2018, vol. 19, num. 5, p. E1361
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/712754/EU//BEST
dc.relation.urihttp://dx.doi.org/10.3390/ijms19051361
dc.rightscc by (c) Martí Coma Cros et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationMalària
dc.subject.classificationNanomedicina
dc.subject.otherMalaria
dc.subject.otherNanomedicine
dc.titleAntimalarial Activity of Orally Administered Curcumin Incorporated in Eudragit((R))-Containing Liposomes
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
marticoma-cros2018_3041.pdf
Mida:
1.15 MB
Format:
Adobe Portable Document Format